Bausch Health unveils new skin resurfacing laser at ASLMS 2025

ORLANDO, FL - Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its aesthetics division, Solta Medical, announced the launch of their latest skin resurfacing technology, Fraxel FTX™, at the American Society for Laser Medicine & Surgery (ASLMS) 2025 Annual Conference today. The product will be available to dermatologists, plastic surgeons, and licensed aesthetic professionals across the United States, with an expansion plan set for global markets in the upcoming months. With the company’s earnings report due on April 30, 2025, InvestingPro subscribers can access exclusive insights and detailed analysis through the comprehensive Pro Research Report, available for over 1,400 US stocks.

Fraxel FTX™ represents an advancement in the Fraxel® brand, which is known for treating skin concerns such as sun damage, wrinkles, acne scars, and pigmentation irregularities. The new system is designed to deliver noticeable results after a single treatment across all skin types. It incorporates a dual wavelength fractional laser, combining a 1550 nm erbium-glass laser and a 1927 nm thulium laser to target both superficial and deeper skin layers.

The technology also features a redesigned ergonomic handpiece that is 20% lighter and smaller, with integrated cooling to enhance patient comfort. An intelligent optical tracking system with AccuTRAC™ ensures efficient and consistent delivery of the treatment. Additionally, the console and user interface have been modernized to provide aesthetic professionals with flexible and personalized treatment settings.

Thomas J. Appio, CEO of Bausch Health, expressed the company’s commitment to advancing aesthetic medicine and enhancing patient experiences with the introduction of Fraxel FTX™. Jiny Kim, Senior Vice President at Solta Medical, highlighted the system’s combination of trusted laser technology with new ergonomic and efficiency improvements.

The Fraxel FTX™ Laser System is indicated for various dermatological procedures, including skin resurfacing, treatment of dyschromia and cutaneous lesions, and improvement of periorbital wrinkles, acne scars, and surgical scars. It is also indicated for the treatment of pigmented lesions and actinic keratosis.

The company has provided important safety information, including contraindications and potential adverse events, advising medical judgment in treating patients with certain conditions and emphasizing the need for protective eyewear during laser treatments.

This launch is part of Bausch Health’s broader strategy to become a globally integrated healthcare company with a focus on delivering better health care outcomes. With analysts predicting profitability this year and management actively buying back shares, the company shows promising signs of executing its growth strategy. For deeper insights into Bausch Health’s financial health and growth prospects, including 8 additional exclusive ProTips, visit InvestingPro. The information is based on a press release statement from Bausch Health Companies Inc.

In other recent news, Bausch Health Companies Inc. has been in the spotlight due to several significant developments. The company disclosed that activist investor Carl Icahn has acquired an economic interest covering approximately 34% of its outstanding shares through equity swaps, as detailed in a recent proxy statement supplement. Additionally, Fitch Ratings upgraded Bausch Health’s Issuer Default Ratings to ’CCC+’ from ’CCC’, citing a successful refinancing effort that addressed upcoming debt maturities. This upgrade also extended to Bausch Health’s subsidiary, Bausch Health Americas, Inc.

Moreover, Bausch Health secured a legal victory when the U.S. District Court for the District of Columbia ruled in favor of its subsidiary, Salix Pharmaceuticals, maintaining market exclusivity for XIFAXAN® until at least June 2028. The company also adopted a shareholder rights plan to prevent takeovers that could disproportionately benefit certain shareholders. Meanwhile, Bausch + Lomb, a subsidiary of Bausch Health, received a rating upgrade from Fitch Ratings to ’B’ from ’B-’, with the agency maintaining a Rating Watch Evolving.

These developments reflect a period of strategic maneuvers and legal victories for Bausch Health, with implications for its financial and operational landscape. Investors are keenly awaiting the company’s first-quarter financial results, scheduled for release on April 30, 2025, which will provide further insights into its performance. The company’s proactive governance measures and recent legal win have contributed to a positive investor sentiment, bolstered by the influence of high-profile investors like Carl Icahn.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.